Pallas Capital Advisors LLC Coherus Bio Sciences, Inc. Transaction History
Pallas Capital Advisors LLC
- $2.43 Billion
- Q2 2025
A detailed history of Pallas Capital Advisors LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 13,696 shares of CHRS stock, worth $12,600. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,696
Previous 12,758
7.35%
Holding current value
$12,600
Previous $10,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CHRS
# of Institutions
121Shares Held
64.4MCall Options Held
96.6KPut Options Held
65.3K-
Black Rock Inc. New York, NY11.8MShares$10.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$10.3 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$4.84 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$4.69 Million0.27% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$2.79 Million0.11% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $71.5M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...